Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2017 (2017), Article ID 4240959, 4 pages
https://doi.org/10.1155/2017/4240959
Case Report

Simultaneous Left Ventricular and Deep Vein Thrombi Caused by Protein C Deficiency

Department of Surgery, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka 426-8677, Japan

Correspondence should be addressed to Harufumi Maki

Received 30 September 2016; Accepted 29 December 2016; Published 17 January 2017

Academic Editor: Michael S. Firstenberg

Copyright © 2017 Harufumi Maki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Tait, I. D. Walker, P. H. Reitsma et al., “Prevalence of protein C deficiency in the healthy population,” Thrombosis and Haemostasis, vol. 73, no. 1, pp. 87–93, 1995. View at Google Scholar · View at Scopus
  2. T. Koster, F. R. Rosendaal, E. Briet et al., “Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study),” Blood, vol. 85, no. 10, pp. 2756–2761, 1995. View at Google Scholar · View at Scopus
  3. S. Maqbool, V. Rastogi, A. Seth, S. Singh, V. Kumar, and A. Mustaqueem, “Protein-C deficiency presenting as pulmonary embolism and myocardial infarction in the same patient,” Thrombosis Journal, vol. 11, no. 1, article 19, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Kario, T. Matsuo, S. Tai et al., “Congenital protein c deficiency and myocardial infarction: concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis,” Thrombosis Research, vol. 67, no. 1, pp. 95–103, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. A. R. Folsom, T. Ohira, K. Yamagishi, and M. Cushman, “Low protein C and incidence of ischemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study,” Journal of Thrombosis and Haemostasis, vol. 7, no. 11, pp. 1774–1778, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Kenet, L. K. Lütkhoff, M. Albisetti et al., “Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies,” Circulation, vol. 121, no. 16, pp. 1838–1847, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Hermans, S. Eeckhoudt, and C. Lambert, “Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency,” Thrombosis and haemostasis, vol. 107, no. 6, pp. 1189–1191, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. P. Boey, A. Jolley, C. Nicholls et al., “Novel protein C gene mutation in a compound heterozygote resulting in catastrophic thrombosis in early adulthood: diagnosis and long-term treatment with subcutaneous protein C concentrate,” British Journal of Haematology, vol. 172, no. 5, pp. 811–813, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Delewi, F. Zijlstra, and J. J. Piek, “Left ventricular thrombus formation after acute myocardial infarction,” Heart, vol. 98, no. 23, pp. 1743–1749, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Nagamoto, T. Shiomi, T. Matsuura et al., “Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran,” Heart and Vessels, vol. 29, no. 4, pp. 560–562, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Chung, Y. M. Paek, H. J. Lee, and K.-S. Hong, “Dabigatran effect on left ventricular thrombus in a patient with acute ischemic stroke,” Journal of Stroke, vol. 17, no. 3, pp. 366–368, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Nakasuka, S. Ito, T. Noda et al., “Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban,” Case Reports in Medicine, vol. 2014, Article ID 814524, 5 pages, 2014. View at Publisher · View at Google Scholar
  13. S. Kurisu, I. Inoue, T. Kawagoe et al., “Left ventricular apical thrombus formation in a patient with suspected tako-tsubo-like left ventricular dysfunction,” Circulation Journal, vol. 67, no. 6, pp. 556–558, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Ranucci, G. Isgrò, A. Cazzaniga et al., “Different patterns of heparin resistance: therapeutic implications,” Perfusion, vol. 17, no. 3, pp. 199–204, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Finley and C. Greenberg, “Heparin sensitivity and resistance: management during cardiopulmonary bypass,” Anesthesia and Analgesia, vol. 116, no. 6, pp. 1210–1222, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Kennedy and C. Alaniz, “Apparent argatroban resistance in a patient with elevated factor VIII levels,” Annals of Pharmacotherapy, vol. 47, no. 7-8, p. e29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Harder, “Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism,” Thrombosis Journal, vol. 12, no. 1, article 22, 2014. View at Publisher · View at Google Scholar · View at Scopus